Expanded Access in Pancreatic Cancer Clinical Trial
Official title:
Expanded Access to RBS2418 for an Individual Patient With Pancreatic Cancer
This is an expanded access treatment protocol designed to provide access of RBS2418 to a single patient with pancreatic cancer.
Given lack of any therapeutic options such as standard of care chemotherapy for this single patient owing to lack of tolerability and opportunity to enroll in any clinical trial due to extent of disease, patient desires to try compassionate use protocol with RBS2418, an oral immunotherapeutic agent that is currently in clinical trials and is well tolerated by patients. Furthermore, patient's tumor has been shown to express ENPP1, the protein targeted by RBS2418 ;